FY2017 EPS Estimates for Syros Pharmaceuticals Inc Lowered by Wedbush (SYRS)
Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Wedbush dropped their FY2017 earnings per share estimates for Syros Pharmaceuticals in a research report issued to clients and investors on Tuesday. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($2.10) per share for the year, down from their previous estimate of ($1.99). Wedbush also issued estimates for Syros Pharmaceuticals’ Q4 2017 earnings at ($0.56) EPS, Q1 2018 earnings at ($0.46) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.65) EPS, FY2018 earnings at ($2.24) EPS, FY2019 earnings at ($2.26) EPS, FY2020 earnings at ($1.99) EPS and FY2021 earnings at ($1.82) EPS.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.53).
Shares of Syros Pharmaceuticals (SYRS) opened at $8.98 on Thursday. Syros Pharmaceuticals has a one year low of $6.30 and a one year high of $24.38.
Institutional investors have recently made changes to their positions in the business. Nationwide Fund Advisors increased its holdings in Syros Pharmaceuticals by 249.8% in the 2nd quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock valued at $113,000 after buying an additional 5,016 shares during the period. Russell Investments Group Ltd. bought a new stake in Syros Pharmaceuticals in the 3rd quarter valued at $133,000. Cubist Systematic Strategies LLC bought a new stake in Syros Pharmaceuticals in the 3rd quarter valued at $149,000. The Manufacturers Life Insurance Company increased its holdings in Syros Pharmaceuticals by 11,253.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after buying an additional 10,466 shares during the period. Finally, Rhumbline Advisers bought a new stake in Syros Pharmaceuticals in the 2nd quarter valued at $198,000. 58.02% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Srinivas Akkaraju bought 109,774 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, with a total value of $991,259.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 33.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “FY2017 EPS Estimates for Syros Pharmaceuticals Inc Lowered by Wedbush (SYRS)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/fy2017-eps-estimates-for-syros-pharmaceuticals-inc-lowered-by-wedbush-syrs/1764682.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.